What are your top takeaways in Thoracic Cancers from ASCO 2026?

ASCO 2026 included a wealth of important trials for lung cancer. I will focus on moving the needle for targeted therapy with my top 3 below:

1. LIBRETTO-432 showed a highly significant improvement in DFS with selpercatinib following resection for stage II-IIIA RET fusion-positive NSCLC. The results led...

At the ASCO 2026 meeting, two important trials on NSCLC were presented in the Plenary Session that may have a significant impact on future management in these patient populations.

Phase III LIBRETTO trial- 432: Presented in this year's ASCO Plenary Session. This trial included NSCLC with a RET fusio...

• CROWN trial 7-year data: This update shows that the activity of lorlatinib continues to be very durable, which continues to support its role as a frontline therapy for metastatic ALK NSCLC. However, the toxicities and side effects remain challenging, and we need to investigate what supportive thera...

• EGFR- It is “uncommon” to see such nice updates on atypical EGFR mutations and EGFR exon 20 insertions. CHRYSALIS-2 cohort of patients with atypical EGFR mutations treated with amivantamab/lazertinib now provides an OS update following prior eye-popping PFS results of 19 months or so. Very impressi...

At ASCO 2026, many important studies in Lung cancer were presented, but these three are my top picks.

• The first is the LIBRETTO-432 trial, which is a double-blind, placebo-controlled phase III trial in which patients with stage IB-IIIA RET+ NSCLC after definitive local therapy (Surgery or radiothera...

While I believe there was a lot of exciting data presented at ASCO 2026 and it is very challenging to limit my favorite abstracts to just three, I believe the following three abstracts were most impactful:

ABSTRACT 8000: ECOG-ACRIN EA5142

This was a very important presentation and reinforces my growin...

• 7-year CROWN data- solidifies lorlatinib as the best first-line treatment for patients with ALK fusion-positive NSCLC.

• Clinical validity of ultrasensitive single-digit parts per million ctDNA detection in non–small cell lung cancer: MRD assays are getting better, and more sensitive assays may all...

• LIBRETTO-432, which investigated 3 years of adjuvant selpercatinib versus placebo in Stage IB-IIIA RET-fusion + NSCLC after definitive surgery or radiation followed by systemic chemotherapy (as applicable). The primary analysis population was based on 109 patients with stage II or IIIA NSCLC who we...

• Abstract 8008 – ABBV-706 SEZ6 ADC in relapsed SCLC - SEZ6 appears to be a good target, as it is very commonly expressed in SCLC. Anti-SCLC activity of single-agent therapy in a good-sized cohort of relatively heavily pretreated patients (n=124) was encouraging, with an ORR of 56% and a median OS of...

• LBA8500 - Sunvozertinib monotherapy versus platinum-based chemotherapy as first-line treatment for advanced NSCLC with EGFR exon20ins: Primary analysis of a multinational phase 3 randomized study (WU-KONG28). WU-KONG28 (NCT05668988) was a multinational randomized phase 3 study comparing sunvozertin...